Monoclonal antibodies targeting Notch ligands such as Jagged1, Jagged2, and Delta-like can specifically block the binding of Notch receptors to their ligands, thereby inhibiting the activation of Notch signaling (139) Studies have found that monoclonal antibodies targeting Jagged1 and Jagged2 also exhibit tumor growth inhibitory effects in certain cancer types. Here, JAG2 is linked to neoplasm.